



**The Therapeutic Use of Psychedelic Drugs:
Legal, Policy and Neuroscience Perspectives
A Symposium at the Washington College of Law
April 12, 2024**



8:00 a.m. Doors open: Coffee, Tea, Light Pastries

8:50 a.m. Welcome

Terry Davidson, PhD, Professor, Director of the Center for Neuroscience and Behavior, American University

Maya Manian, JD, Professor, Faculty Director of the Health Law and Policy Program, Washington College of Law
American University

Vicky Wilkins, PhD, Acting Provost, Professor, School of Public Affairs, American University

9:00 a.m. Keynote: History & Current Status of the Psychedelic Field (introduction: Prof. Lewis Grossman)

Rick Doblin, PhD, Founder and President, Multidisciplinary Association for Psychedelic Studies

9:30 a.m. Unconventional Warfare for Mental Health: A Navy SEAL's Journey with Psychedelic Therapies (introduction: Prof. Anthony Riley)

Marcus Capone: Chairman/Founder of VETS, Inc Founder/CEO of TARA Mind, Inc.

9:55 a.m. Patient's Experience: The Last Resort for the First Study Participant (intro. Prof. Anthony Riley)

Jon Kostas: CEO & Director Apollo Pact

10:20 a.m. Break

10:30 a.m. Psychedelics: A New Paradigm in Mental Health Treatment (Introduction: Prof. Anthony Riley)

Matthew Johnson, PhD, Senior Investigator, Sheppard Pratt

11:15 a.m. Deconstructing the Psychedelic Experience-Therapeutic Mechanisms of an Emerging Drug Class (introduction: Prof. Anthony Riley)

Boris Heifets, MD, PhD, Associate Professor, Department of Anesthesiology, Perioperative and Pain
Medicine, Stanford University School of Medicine

Noon Lunch Break (lunch will be provided)

12:30 p.m. Keynote: Branching Paths and Dead Ends for Regulatory Models for Psychedelics

(Introduction: Prof. Lewis Grossman)

Glen Cohen, JD, Professor, Harvard Law School, Lead, Harvard Law School Project on
Psychedelics Law, and Regulation

1:00 p.m. Panel: Ethical Issues in Psychedelic Drug Research and Therapy (Moderator: Prof. Susan Carle)

The Virtuous Psychedelic Clinician: Ethical Values & Practices

Dominic Sisti, PhD. Associate Professor Department of Medical Ethics & Health Policy, University of
Pennsylvania

Challenges in Ensuring Appropriate Use of Psychedelics in Clinical Settings

Paul Appelbaum, MD, Professor of Psychiatry and Director of the Center for Law, Ethics and
Psychiatry, College of Physicians and Surgeons of Columbia University

Psychedelic Retreats, Healthcare Gatekeeping, and Physician Readiness

Amy Lynn McGuire, JD, PhD, Professor of Biomedical Ethics, Director of the Center for Medical
Ethics and Health Policy, Baylor College of Medicine

Continued on the next page

- 2:00 p.m. Psychedelics and Racial Justice** (introduction: Professor Susan Carle)
Monnica Williams, PhD, Professor, School of Psychology, University of Ottawa, Ottawa, Canada
- 2:30 p.m. Panel: Emerging Areas of Public Health Interest** (Moderator: Prof. Erdal Tekin)
Emerging Therapeutics: Policy Considerations for Psychedelics in Real-World Settings
(co-presented by)
CAPT Sean J. Belouin, PharmD, Senior Advisor on Behavioral Health, Office of Science and Medicine (OSM), Office of the Assistant Secretary for Health (OASH), Department of Health and Human Services (HHS)
Leith J. States, MD, MPH, MBA, FACPM, Chief Medical Officer to the Assistant Secretary for Health and Deputy Director of the Office of Science and Medicine, Office of the Assistant Secretary for Health/HHS
Considering Alternatives to Psychedelic Drug Prohibition
Beau Kilmer, PhD, Senior policy researcher at the RAND Corporation, Chair in Drug Policy Innovation, Codirector of the RAND Drug Policy Research Center
- 3:30 p.m. Break**
- 3:45 p.m. Panel: State and Federal Policies and Regulations** (Moderator: Prof. Asha Scielzo)
Regulation of Psychedelics Under the Controlled Substances Act: Challenges and Solutions
Lewis Grossman, JD, PhD, Ann Loeb Bronfman Professor of Law & Affiliate Professor of History, American University Washington College of Law
Psychedelic Drug Development: Regulatory Perspective from the US Food and Drug Administration
Tiffany Farchione, PhD, Director, Division of Psychiatry, Center for Drug Evaluation and Research, U.S. Food and Drug Administration
Implementing the Nation's First Regulatory Framework for Psilocybin Services: An Oregon Update
Angela Allbee, Manager, Psilocybin Services Section, Oregon Health Authority
- 4:45 p.m. Panel: Commercialization issues** (Moderator Prof. Charles Duan)
A Trip Across the Psychedelic Patent Landscape
Graham Pechenik, JD, Founder & Registered Patent Attorney, Calyxlaw
Overcoming Challenges in Psychedelic Drug Development: A Focus on Psilocybin
Jim Gilligan, PhD, MBIS, President and Chief Scientific Officer, Tryp Therapeutics
- 5:25 p.m. Closing Remarks and Adjournment**